Aarti Pharmalabs Limited (NSE:AARTIPHARM)
India
· Delayed Price · Currency is INR 700.15
+1.30 (0.19%)
At close: Mar 6, 2026
Aarti Pharmalabs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Revenue | 18,006 | 21,151 | 18,526 | 19,452 | 11,999 | - | Upgrade
|
| Revenue Growth (YoY) | -12.47% | 14.17% | -4.76% | 62.11% | - | - | Upgrade
|
| Cost of Revenue | 8,771 | 11,744 | 10,608 | 12,046 | 7,470 | - | Upgrade
|
| Gross Profit | 9,235 | 9,407 | 7,918 | 7,406 | 4,529 | - | Upgrade
|
| Selling, General & Admin | 1,752 | 1,658 | 1,463 | 1,349 | 852.03 | - | Upgrade
|
| Other Operating Expenses | 3,303 | 3,105 | 2,598 | 2,637 | 1,608 | 0.05 | Upgrade
|
| Operating Expenses | 6,046 | 5,632 | 4,790 | 4,611 | 2,881 | 0.05 | Upgrade
|
| Operating Income | 3,189 | 3,775 | 3,128 | 2,795 | 1,648 | -0.05 | Upgrade
|
| Interest Expense | -366.23 | -268.96 | -172.15 | -210.52 | -3.4 | - | Upgrade
|
| Interest & Investment Income | 71.47 | 71.47 | 30.74 | 21.87 | 24.84 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 16.93 | 16.93 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -91.8 | 12.72 | 12.52 | 1.85 | -116.1 | - | Upgrade
|
| EBT Excluding Unusual Items | 2,844 | 3,607 | 2,999 | 2,608 | 1,554 | -0.05 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 5.51 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.08 | 0.08 | 0.19 | -0.58 | 0.21 | - | Upgrade
|
| Pretax Income | 2,817 | 3,607 | 3,005 | 2,608 | 1,554 | -0.05 | Upgrade
|
| Income Tax Expense | 679.15 | 882.85 | 835.9 | 672.78 | 331.29 | - | Upgrade
|
| Net Income | 2,137 | 2,724 | 2,169 | 1,935 | 1,223 | -0.05 | Upgrade
|
| Net Income to Common | 2,137 | 2,724 | 2,169 | 1,935 | 1,223 | -0.05 | Upgrade
|
| Net Income Growth | -14.27% | 25.59% | 12.10% | 58.27% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 91 | 91 | 91 | 91 | 91 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 91 | 91 | 91 | 91 | 91 | 0 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.07% | 0.01% | - | 36150.40% | - | Upgrade
|
| EPS (Basic) | 23.59 | 30.06 | 23.93 | 21.35 | 13.49 | -0.18 | Upgrade
|
| EPS (Diluted) | 23.56 | 30.04 | 23.93 | 21.35 | 13.49 | -0.18 | Upgrade
|
| EPS Growth | -14.33% | 25.53% | 12.08% | 58.27% | - | - | Upgrade
|
| Free Cash Flow | - | -704.76 | 607.5 | 1,480 | -1,849 | - | Upgrade
|
| Free Cash Flow Per Share | - | -7.77 | 6.70 | 16.33 | -20.40 | - | Upgrade
|
| Dividend Per Share | 4.000 | 5.000 | 3.000 | 2.000 | - | - | Upgrade
|
| Dividend Growth | 14.29% | 66.67% | 50.00% | - | - | - | Upgrade
|
| Gross Margin | 51.29% | 44.47% | 42.74% | 38.07% | 37.74% | - | Upgrade
|
| Operating Margin | 17.71% | 17.85% | 16.89% | 14.37% | 13.74% | - | Upgrade
|
| Profit Margin | 11.87% | 12.88% | 11.71% | 9.95% | 10.19% | - | Upgrade
|
| Free Cash Flow Margin | - | -3.33% | 3.28% | 7.61% | -15.40% | - | Upgrade
|
| EBITDA | 4,019 | 4,539 | 3,804 | 3,421 | 2,069 | - | Upgrade
|
| EBITDA Margin | 22.32% | 21.46% | 20.54% | 17.58% | 17.25% | - | Upgrade
|
| D&A For EBITDA | 829.85 | 764.05 | 676.32 | 625.43 | 421.19 | - | Upgrade
|
| EBIT | 3,189 | 3,775 | 3,128 | 2,795 | 1,648 | -0.05 | Upgrade
|
| EBIT Margin | 17.71% | 17.85% | 16.89% | 14.37% | 13.74% | - | Upgrade
|
| Effective Tax Rate | 24.11% | 24.48% | 27.82% | 25.80% | 21.32% | - | Upgrade
|
| Revenue as Reported | 18,002 | 21,252 | 18,575 | 19,476 | 12,025 | - | Upgrade
|
| Advertising Expenses | - | 26.39 | 64.11 | 51.61 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.